
Checkpoint Therapeutics CKPT
Checkpoint Therapeutics EV - Enterprise Value | CKPT
Annual EV - Enterprise Value Checkpoint Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 174 M | 49.9 M | 53.5 M | -15.1 M | 148 M | 45.9 M | 99.3 M | 77.6 M | 206 M | -46.2 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 206 M | -46.2 M | 79.2 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
673 M | $ 4.21 | 4.99 % | $ 653 M | ||
|
AbbVie
ABBV
|
394 B | $ 291.22 | 1.06 % | $ 515 B | ||
|
22nd Century Group
XXII
|
1.92 M | $ 1.56 | -19.17 % | $ 287 K | ||
|
Axon Enterprise
AXON
|
33.2 B | $ 313.68 | -18.01 % | $ 24.5 B | ||
|
Biogen
BIIB
|
37.6 B | $ 248.51 | 1.88 % | $ 36.4 B | ||
|
BioLineRx Ltd.
BLRX
|
5.66 B | $ 1.73 | -2.15 % | $ 4.26 B | ||
|
Theratechnologies
THTX
|
139 M | - | - | $ 83.9 M | ||
|
Exelixis
EXEL
|
11.9 B | $ 69.55 | 1.22 % | $ 18.9 B | ||
|
Geron Corporation
GERN
|
1.33 B | $ 0.99 | 3.97 % | $ 660 M | ||
|
Gilead Sciences
GILD
|
176 B | $ 166.9 | -0.4 % | $ 208 B | ||
|
Grifols, S.A.
GRFS
|
16.3 B | $ 8.46 | -0.12 % | $ 5.75 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
43.3 B | $ 155.97 | -0.44 % | $ 20.4 B | ||
|
InflaRx N.V.
IFRX
|
60.9 M | $ 1.31 | -3.69 % | $ 88.1 M | ||
|
INmune Bio
INMB
|
12.3 M | $ 1.12 | -4.68 % | $ 27.7 M | ||
|
Insmed Incorporated
INSM
|
32.6 B | $ 114.55 | 5.32 % | $ 22.8 B | ||
|
Johnson & Johnson
JNJ
|
98 B | $ 274.89 | 0.95 % | $ 662 B | ||
|
Titan Pharmaceuticals
TTNP
|
-2.35 M | - | -3.76 % | $ 3.47 M | ||
|
Lineage Cell Therapeutics
LCTX
|
450 M | $ 1.02 | 3.75 % | $ 235 M | ||
|
BioVie
BIVI
|
-12.6 M | $ 1.33 | 9.92 % | $ 1.96 M | ||
|
Longeveron
LGVN
|
16.9 B | $ 1.82 | 6.43 % | $ 32 B | ||
|
Allena Pharmaceuticals
ALNA
|
11.9 M | - | 3.16 % | $ 1.9 M | ||
|
TCR2 Therapeutics
TCRR
|
92.6 M | - | - | $ 58.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
4.14 B | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Mustang Bio
MBIO
|
-5.03 M | $ 0.39 | 0.15 % | $ 1.91 M | ||
|
TFF Pharmaceuticals
TFFP
|
7.83 M | - | -60.05 % | $ 125 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 1.63 | 1.87 % | $ 2.68 M | ||
|
Mesoblast Limited
MESO
|
12.6 B | $ 14.26 | 1.13 % | $ 17.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 93.81 | 0.28 % | $ 4.71 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
143 M | - | -15.15 % | $ 60.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
111 M | - | - | $ 521 M | ||
|
Codexis
CDXS
|
157 M | $ 1.09 | 6.37 % | $ 95 M | ||
|
MannKind Corporation
MNKD
|
1.76 B | $ 3.91 | 4.0 % | $ 1.2 B | ||
|
MediciNova
MNOV
|
42.4 M | $ 1.44 | -0.69 % | $ 70.7 M | ||
|
Axcella Health
AXLA
|
22.6 M | - | -16.42 % | $ 249 M | ||
|
Merck & Co.
MRK
|
296 B | $ 146.81 | -0.07 % | $ 367 B | ||
|
Dynavax Technologies Corporation
DVAX
|
2.02 B | - | - | $ 2.02 B | ||
|
Tyme Technologies
TYME
|
-5.81 M | - | 8.07 % | $ 54 M | ||
|
Curis
CRIS
|
18.9 M | $ 0.88 | 3.67 % | $ 11.6 M | ||
|
Cyclerion Therapeutics
CYCN
|
10.1 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Завод ДИОД
DIOD
|
3.14 B | - | - | - | ||
|
CorMedix
CRMD
|
276 M | $ 5.31 | 1.43 % | $ 383 K | ||
|
Novartis AG
NVS
|
369 B | $ 162.64 | 0.44 % | $ 315 B | ||
|
CRISPR Therapeutics AG
CRSP
|
4.38 B | $ 50.09 | 3.15 % | $ 4.5 B | ||
|
PDS Biotechnology Corporation
PDSB
|
19.6 M | $ 1.22 | 4.27 % | $ 56.6 M | ||
|
Pfizer
PFE
|
275 B | $ 29.39 | -0.22 % | $ 167 B | ||
|
Pharming Group N.V.
PHAR
|
11.8 B | $ 12.32 | 0.16 % | $ 8.49 B | ||
|
Orgenesis
ORGS
|
38.8 M | - | -33.86 % | $ 61.2 M | ||
|
Cytokinetics, Incorporated
CYTK
|
1.97 B | $ 53.74 | -3.26 % | $ 6.45 M | ||
|
Фармсинтез
LIFE
|
59.3 B | - | - | - | ||
|
Prothena Corporation plc
PRTA
|
-10.4 M | $ 7.93 | 0.51 % | $ 427 M |